Data compiled by Redley Lamar · ChainSifter Intelligence
6Suppliers
10Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Actinium Pharmaceuticals, Inc. (ATNM) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
20Total relationships
3Distinct source URLs
11High confidence
0.811Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Actinium Pharmaceuticals, Inc. Suppliers
Ticker
Name
Confidence
Evidence
AC-225-AND-OTHER-RADIOISOTOPES-SUPPLIERS
AC-225-AND-OTHER-RADIOISOTOPES-SUPPLIERS
92%
We maintain supply agreements with multiple domestic and international suppliers of Ac-225 and other radioisotopes, providing priority access and redundancy to ensure reliable supply.
CONTRACT-MANUFACTURING-ORGANIZATIONS
CONTRACT-MANUFACTURING-ORGANIZATIONS
92%
We have qualified multiple contract manufacturers capable of producing our drug products under cGMP conditions.
RADIOPHARMACEUTICAL-LOGISTICS-PROVIDERS
RADIOPHARMACEUTICAL-LOGISTICS-PROVIDERS
92%
We have established relationships with specialized radiopharmaceutical logistics providers capable of cold-chain distribution, real-time tracking, and just-in-time delivery to clinical sites and comm…
Reciprocal relationship from CNSP graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from CNSP graph: & Oncology Neurological disorders represent a staggering public health crisi…
Reciprocal relationship from DRTS graph: e term sheets, effective for a 15-year term following the approval to sell our products, Medison will be responsible for performing regulatory submissions, ma…
Reciprocal relationship from TLX graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from TLX graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from TLX grap…
Actinium Pharmaceuticals, Inc. Customers
Ticker
Name
Confidence
Evidence
IMMEDICA-PHARMA-AB
IMMEDICA-PHARMA-AB
92%
Upon signing, the Company was entitled to an upfront, non-refundable payment of $ 35 million from Immedica, which was received in May 2022.
JONESTRADING-INSTITUTIONAL-SERVICES-LLC
JONESTRADING-INSTITUTIONAL-SERVICES-LLC
90%
In August 2020, the Company entered into the Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC, “JonesTrading”, pursuant to which the Company may sell, from time to time…
B-RILEY-SECURITIES-INC
B-RILEY-SECURITIES-INC
85%
On June 28, 2022, the Company entered into an Amended and Restated Capital on Demand™ Sales Agreement (the “A&R Sales Agreement”) with JonesTrading and B. Riley Securities, Inc. ("B. Riley").
GOVERNMENT-SPONSORED-ENTITY
GOVERNMENT-SPONSORED-ENTITY
80%
The Company has a grant from a government-sponsored entity for research and development related activities that provides for payments for reimbursed costs, which included overhead and general and adm…
eferred to and treated in comprehensive treatment centers for in-patient treatment as opposed to community, outpatient-based care. As a result, we believe the majority of AML and High-risk MDS patien…
Reciprocal relationship from KURA graph: Reciprocal relationship from ATNM graph: eferred to and treated in comprehensive treatment centers for in-patient treatment as opposed to community, outpatien…
Reciprocal relationship from MNPR graph: ing on new radiopharmaceutical compounds and linkers. 11 Table of Contents Manufacturing ALXN1840 We do not currently own or operate manufacturing facilities …
eferred to and treated in comprehensive treatment centers for in-patient treatment as opposed to community, outpatient-based care. As a result, we believe the majority of AML and High-risk MDS patien…
Reciprocal relationship from SNDX graph: Reciprocal relationship from ATNM graph: Reciprocal relationship from SNDX graph: Reciprocal relationship from ATNM graph: eferred to and treated in comprehen…
DELAWARE-GENERAL-CORPORATION
DELAWARE-GENERAL-CORPORATION
62%
ecessary funds, or they might not be available to us on acceptable terms or at all. We may also seek to raise funds by selling shares of our preferred or common stock, which could dilute each current…
Actinium Pharmaceuticals, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
ATNM-DEBT-7949
Warrants outstanding: 0.003
90%
xbrl warrant detail from xbrl 2022-12-31.
ATNM-DEBT
Debt stack $1.7M
90%
Market cache reports total debt of $1.7M.
ATNM-DEBT-7950
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2012-12-31.
Actinium Pharmaceuticals, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Actinium Pharmaceuticals, Inc..
Actinium Pharmaceuticals, Inc. Ownership
Holder
Name
Confidence
Evidence
ATNM-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC
VANGUARD CAPITAL MANAGEMENT LLC
90%
13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 58 tracked holders.
Actinium Pharmaceuticals, Inc. Extended Supply Chain Network
